Zhang J, Ding Y, Wang P, Li L, et al. Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in patients from China mainland, Taiwan, and South Korea with moderate to severe plaque psoriasis: a phase 3 randomized clinical trial. Br J Dermatol 2024 Oct 22:ljae406. doi: 10.1093.
PMID: 39437312